Monitor for future announcements regarding asset acquisitions or partnerships; any material deal could significantly impact the company’s valuation given its small market cap ($4M). However, near-term impact is limited due to lack of concrete terms.
Price Chart
Executive Summary
Oragenics, Inc. announced it is exploring potential acquisitions of CNS-focused assets that align with its proprietary intranasal delivery platform, as part of a broader strategy to expand its brain health pipeline. The move is strategic and forward-looking, but no definitive agreements have been reached.
Key Facts
- Oragenics is exploring discussions with third parties for potential acquisition of CNS assets focused on brain health and recovery.
- No definitive agreements have been reached; there is no assurance any deal will be completed.
- The initiative is separate from its AI-driven partnership with Receptor.AI.
- The company continues to advance its lead candidate ONP-002 through Phase IIa trials in Australia, with U.S. Phase IIb trials planned for 2027.
- ONP-002 targets concussion and mild traumatic brain injury, with no FDA-approved pharmacological treatments currently available.
Financial Impact
No financial impact at this stage — exploratory discussions only, no transaction details disclosed.
Risk Factors
- No assurance that any acquisition will be completed.
- Execution risk in integrating new assets, should a deal occur.
- Limited financial resources may constrain ability to close or fund post-acquisition development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253753 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 5w ago | 8-K | $0.5000 $0.4469 | ▼ −10.62% | ▼ −13.80% | $0.3736 (−25.28%) |
Aug 28, 2026 8w ago | 8-K | $0.5098 $0.4800 | ▲ +5.85% | ▲ +5.66% | $0.3736 (+26.72%) |
May 20, 2026 22w ago | DEFA14A | $0.5900 $0.5882 | ▼ −0.31% | ▼ −0.64% | $0.3736 (−36.68%) |
May 19, 2026 23w ago | 8-K | $0.5700 $0.6100 | ▲ +7.02% | ▲ +6.03% | $0.3736 (−34.46%) |
May 7, 2026 24w ago | 8-K | $0.6100 $0.6100 | · 0.00% | ▼ −3.14% | $0.3736 (−38.75%) |
Apr 13, 2026 28w ago | 8-K | $0.6800 $0.5600 | ▼ −17.65% | ▼ −25.38% | $0.3736 (−45.06%) |
Mar 25, 2026 30w ago | Press Release | $0.5800 $0.6400 | ▼ −10.34% | ▲ +0.32% | $0.3736 (+35.59%) |
Mar 23, 2026 31w ago | EFFECT | $0.6800 $0.6600 | ▼ −2.94% | ▼ −10.36% | $0.3736 (−45.06%) |
Mar 11, 2026 32w ago | 8-K | $0.9600 $0.6000 | ▼ −37.50% | ▼ −39.48% | $0.3736 (−61.08%) |
Mar 11, 2026 32w ago | Press Release | $0.8800 $0.6200 | ▼ −29.55% | ▼ −30.07% | $0.3736 (−57.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers